APG-1252 (BM-1252), a recently developed drug with high binding affinity to Bcl-2 and Bcl-xL, has been reported to induce mitochondria-dependent apoptosis in leukemia cells in vitro, to achieve complete and persistent tumor regression in multiple tumor xenograft models including ALL, SCLC and colon and breast carcinoma, and shows strong synergy with some chemotherapeutic agents [115,116]. This evidence concerns the gene BCL2 and neoplasm.